BMI1 and breast carcinoma: These studies, therefore, conclude that up-regulation of miR-15a, miR-16 sensitizes breast cancer to chemotherapeutic drug doxorubicin by targeting BMI1 and this approach might be the potential strategy for the treatment of breast cancer.